Sanofi (SNY)
| Market Cap | 135.91B |
| Revenue (ttm) | 48.29B |
| Net Income (ttm) | 8.91B |
| Shares Out | 2.50B |
| EPS (ttm) | 3.54 |
| PE Ratio | 15.20 |
| Forward PE | 10.49 |
| Dividend | $3.58 (6.58%) |
| Ex-Dividend Date | May 6, 2022 |
| Volume | 2,034,618 |
| Open | 54.43 |
| Previous Close | 53.97 |
| Day's Range | 54.16 - 54.53 |
| 52-Week Range | 36.91 - 58.10 |
| Beta | 0.39 |
| Analysts | Buy |
| Price Target | 55.94 (+2.79%) |
| Earnings Date | Apr 27, 2023 |
About SNY
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established p... [Read more]
Financial Performance
In 2022, Sanofi's revenue was 45.39 billion, an increase of 15.86% compared to the previous year's 39.18 billion. Earnings were 8.37 billion, an increase of 34.52%.
Financial numbers in EUR Financial StatementsAnalyst Forecast
According to 31 analysts, the average rating for SNY stock is "Buy." The 12-month stock price forecast is $55.94, which is an increase of 2.79% from the latest price.
News
Press Release: Availability of the Q1 2023 Memorandum for modelling purposes
Availability of the Q 1 202 3 Memorandum for modelling purposes
PROVENTION BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Provention Bio, Inc. - PRVB
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Provention Bio, ...
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
Shares of Sanofi (NASDAQ: SNY) were up 10.20% the week ended March 24, while Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) finished with a gain of 9.68%, following promising news about the companies' ...
Regeneron, Sanofi Look for Billions From COPD Drug
The companies said Dupixent showed positive results in a late-stage study of current or former smokers with the killer disease.
11 Best Consumer Discretionary Stocks of 2023
While you might already know that you can invest in consumer staples like food and tobacco products, you might not know that you can also invest in what people buy when they have more to spend. Consum...
Sanofi (SNY) Moves 6.0% Higher: Will This Strength Last?
Sanofi (SNY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Sanofi's (SNY) Dupixent Meets Goal in Pivotal COPD Study
Sanofi (SNY) and partner Regeneron's (REGN) Dupixent led to a 30% decline in exacerbations per a late-stage pivotal study on chronic obstructive pulmonary disease.
Sanofi, Regeneron shares pop more than 6% after data shows asthma drug Dupixent may also treat COPD
Sanofi and Regeneron unveiled data on their jointly developed drug for a difficult-to-treat chronic lung disorder that analysts say "exceeded expectations."
Regeneron, Sanofi say Dupixent works in COPD
Shares of Regeneron Pharmaceuticals Inc. REGN, -1.11% rallied about 7% in premarket trading on Thursday after the company said a pivotal Phase 3 clinical trial showed that Dupixent reduced exacerbatio...
Press Release: Dupixent® demonstrates potential to become first biologic to treat COPD by showing significant reduction in exacerbations in pivotal trial
Dupixent ® demonstrates potential to become first biologic to treat COPD by showing significant reduction in exacerbations in pivotal trial
European Dividend Aristocrats: The Best European Dividend Stocks
Similar to their American counterparts, the European Dividend Aristocrats offer investors dividend hikes and blue-chip stability.
Sanofi's (SNY) Dupixent Gets EU Nod for Eczema in Young Kids
Sanofi (SNY) and Regeneron's Dupixent becomes the first and only targeted medicine approved to treat severe atopic dermatitis in kids as young as six months old in Europe.
Press Release: Dupixent® (dupilumab) approved by European Commission as first and only targeted medicine for children as young as six months old with severe atopic dermatitis
Dupixent ® (dupilumab) a pproved by European Commission as f irst and o nly t argeted m edicine for c hildren as y oung as s ix m onths o ld with s evere a topic d ermatitis
Press Release: Dupixent® (dupilumab) late-breaking data at AAD show significant improvements in signs and symptoms of moderate-to-severe atopic hand and foot dermatitis
Dupixent ® (dupilumab) late-breaking data at AAD show significant improvements in signs and symptoms of m oderate-to-severe a topic h and and f oot d ermatitis
Sanofi (SNY) to Reduce Lantus Insulin Price by Up to 78%
Sanofi (SNY) plans to lower the prices of its most widely used insulin Lantus by upto 78% in the United States, effective January 2024.
Sanofi becomes latest to cut insulin prices, joins Novo Nordisk, Eli Lilly
Yahoo Finance's Anjalee Khemlani joins the Live show to report that Sanofi has become the latest major drug company to slash insulin prices, capping the cost at $35.
Sanofi Cuts Insulin Prices Up To 78%—Following Eli Lilly And Novo Nordisk
The French company will cap the monthly cost of insulin at $35, after Novo Nordisk and Eli Lilly also announced major price cuts earlier this month.
Diabetes Drug Giant Sanofi Cuts Insulin Prices by Up to 78%
French drugmaker Sanofi said it would cut the price of some of its insulin products by as much as 78% in the U.S., joining other big diabetes drugmakers facing pressure over high costs.
Sanofi to slash U.S. insulin prices in 2024 after similar cuts by Eli Lilly and Novo Nordisk
The French drugmaker is the last major insulin manufacturer to try to head off government efforts to cap monthly costs by announcing its own steep price cuts.
Sanofi to cap price of Lantus insulin at $35
Sanofi SNY FR:SAN said Thursday that it will cut the U.S. list price of Lantus by 78%, and it will also cap out-of-pocket costs at $35 for the same insulin for people with commercial health insurance,...
Press Release: Sanofi cuts U.S. list price of Lantus®, its most-prescribed insulin, by 78% and caps out-of-pocket Lantus costs at $35 for all patients with commercial insurance
Sanofi cuts U.S. list price of Lantus®, its most-prescribed insulin, by 78% and caps out-of-pocket Lantus costs at $35 for all patients with commercial insurance
This biopharma stock jumped over 250% on Monday: what happened?
Shares of Provention Bio Inc (NASDAQ: PRVB) more than tripled on Monday after Sanofi S.A. (EPA: SAN) confirmed plans of buying the biopharmaceutical company that focused on autoimmune diseases.
Provention Bio Stock Soars on $2.9 Billion Acquisition by Sanofi
The biopharmaceutical company agrees to be acquired by France's Sanofi for $25 a share, or about $2.9 billion.